When someone on cancer treatment is exposed to flu at home, guidelines offer two routes: a preventive course of oseltamivir straight away, or having the tablets ready and starting a full treatment course at the first symptom. The bodies that write the guidelines disagree on which to prefer, and neither route has been tested in people with cancer.
The positions. The German AGIHO guideline (2025) recommends post-exposure prophylaxis for immunocompromised patients with cancer, ideally within 72 hours, graded BIIt, the t meaning the evidence is transferred from other patient groups. The IDSA guideline (2018) says only that prophylaxis can be considered for severely immunocompromised people in whom vaccination is expected to work poorly (C-II), and lists educating patients and arranging early treatment as an alternative (C-III). UKHSA (2026) offers ten days of once-daily oseltamivir to at-risk contacts not adequately protected by vaccination, and allows monitoring with prompt treatment where the patient has chosen it and a pharmacy supply is arranged in advance.
What is not known. The US oseltamivir label states that efficacy for treatment or prophylaxis has not been established in immunocompromised patients. Its household prophylaxis trial, in contacts aged 13 or older not selected for immune status, cut laboratory-confirmed clinical influenza from 12% (24 of 200) to 1% (2 of 205). The same label reports treatment-associated resistance in 27% (8 of 30) of influenza A/H1N1 infections in a treatment study of immunocompromised people. The preventive dose is once a day and the treatment dose twice a day, and UKHSA and IDSA both say to switch to treatment dosing if symptoms start during prophylaxis.
No trial comparing the two routes in people with cancer was found in any source read.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:untested.
Shares the tags protocol-upgrade, upgrade:untested.
Shares the tags protocol-upgrade, upgrade:untested.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/